PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.\', \'Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy. Electronic address: fabrizio.nelli@asl.vt.it.\', \'Clinical Trial Center, Biostatistics and Bioinformatics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.\', \'Department of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of Belcolle, Viterbo, Italy.\', \'Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S2059-7029(21)00312-410.1016/j.esmoop.2021.100350
?:hasPublicationType
?:journal
  • ESMO open
is ?:pmid of
?:pmid
?:pmid
  • 34942438
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34942438>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34942438>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all